Continuing Medical Education
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this live activity for a maximum of 17.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by November 16, 2020. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on this web page and via email. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.
Statement of Educational Need, Target Audience, and Learning Objectives
Myeloma is the second most commonly diagnosed blood cancer in the United States, with an estimated 32,270 new cases in 2020. It is estimated that 12,830 individuals with myeloma will die from the disease in 2020. The overall five-year survival rate for individuals with multiple myeloma is 52%. This greatly increases (to 74%) if the disease is diagnosed at an early stage. However, it is estimated that only 5% of patients are diagnosed with early-stage disease.
There have been advances and improvements of overall survival rates, especially in the last five or six years, as we have seen an increase in FDA-approved drugs and treatment options for the disease. It is estimated that patients receive four or more different lines of therapy during the treatment of their disease. Additional research and collaboration is needed in a variety of areas to optimize current care. Advances in detection, risk assessment, and monitoring are needed to diagnose an earlier stage and to manage care for individuals with precursor conditions. Ongoing efforts in optimizing novel treatments, combination therapies, and immunotherapies are needed to improve outcomes in patients, both newly diagnosed and with relapsed and/or refractory disease.
The research being presented at this conference will address some of the needs mentioned above. The program was designed to discuss advances in basic and translational research (genetics, risk assessment of precursor conditions, monitoring, drug resistance, etc.) and evaluate their application to improve clinical outcomes.
After participating in this CME activity, physicians should be able to:
- Explain the spectrum of precursor conditions and evaluate their risk of progression to myeloma.
- Provide examples of current technologies to diagnose and monitor myeloma and precursor conditions.
- Provide examples of the latest research in myeloma genetics and the study of the myeloma microenvironment.
- Identify current therapeutic options to treat myeloma, including combination therapies and immunotherapeutics.
- Articulate various mechanisms of drug resistance and therapeutic evasion.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
Acknowledgment of Financial or Other Support
This activity is supported by Professional Educational Grants and will be disclosed at the activity.
Questions about CME?
Please contact the Office of CME at (215) 440-9300 or [email protected].